Medical Device Deals Stay Strong in 2016

by | Dec 30, 2016 4:02 pm | Medical Devices

Medical Devices is finishing the year on a high note. In fact, as of December 29, 2016, deal volume reached 113 transactions, equal to 2015’s total. Deal value topped off at $61.3 billion, a 111% increase from last year’s total of $29.1 billion. However, one deal accounted for 50% of 2016’s total, and that is Abbott’s (NYSE: ABT) $30.7 billion purchase of St. Jude Medical, Inc. (NYSE: STJ), a developer, manufacturer and distributor of cardiovascular medical devices for cardiac rhythm management. When that mega deal is subtracted, we get a dollar value of $30.6 billion, still a 5% climb since last year. A handful of acquirers made a name for themselves this year, such as Stryker Corporation... Read More »
J&J Slices Its Medical Device Division

J&J Slices Its Medical Device Division

by | Jan 21, 2016 9:12 pm | Medical Devices

Johnson & Johnson (NYSE: JNJ) announced the restructuring of its medical devices business on January 19, 2016. Its 8K filing noted pre-tax restructuring charges of $2.0 billion to $2.4 billion, expected to be incurred this year, as well as a Q4:15 charge of approximately $600 million. About 4% to 6% of the division’s global workforce will get walking papers over the next two years, resulting in a $500 million charge for severance. On a more upbeat note, JNJ expects to see annualized pre-tax cost savings of $800 million to $1.0 billion. This move comes as the market for medical devices has slowed, particularly in the United States. As one of many cost-cutting measures, U.S.... Read More »

AbbVie Wins Pharmacyclics

by | Mar 9, 2015 7:33 pm | Pharmaceuticals

Everybody hates a winner, it seems. Last week’s announcement that AbbVie Inc. (NYSE: ABBV) won the bidding war for Pharmacyclics Inc. (NASDAQ: PCYC) had many analysts shaking their heads in disbelief. The consternation was over the price, which at $261.25 per share for PCYC came to approximately $21 billion, about 27.8x revenue and 165.6x EBITDA. The real prize for AbbVie is Imbruvica, an effective treatment against a form of leukemia and other diseases that Pharmacyclics is marketing under an agreement with Johnson & Johnson (NYSE: JNJ). J&J and Pfizer (NYSE: PFE) were also in the final round of bidders. AbbVie’s shares fell nearly 6% on March 5, the day after the announcement,... Read More »